Chelators such as DOTA exits but the harsh conditions required for labeling are not compatible with stability of antibodies. Attempts at amelioration typically result in poorer yield, efficiency, and specific activity.
We have developed an octadentate chelator using 3-hydroxy-N-methyl_2-pyridinone (Me-3, 2-HOPO) that can form extremely stable thorium complexes. Th227-[Me-3,2-HOPO]-antibody shows great promise for targeted alpha therapy of a variety of cancers.
Presented By: Olav B. Ryan from Bayer AS, Oslo, Norway
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.